Highlights of the Annual Meeting of the Italian Association for Cell Cultures (AICC): New drug delivery strategies and technological platforms for diagnosis and therapy of tumors (Part I) 6-7 December 2007, Naples, Italy

Michele Caraglia, Monica Marra, Alfredo Budillon

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The application of computational analysis to biochemistry and molecular biology techniques has allowed the design of advanced technological platforms such as DNA microarrays, proteomic analysis and tissue microarrays. These are useful in the diagnosis of tumors and in driving the choice of opportune therapeutic options. The use of target-based agents requires the determination of the molecular features of the tumors. During the AICC meeting four new advanced technological platforms were analyzed: DNA microarrays, ProtoArrays, tissue microarrays and proteomic analysis with differential in-gel electrophoresis (DIGE) and matrix-associated laser desorption ionization-time of flight (MALDI-TOF). The use of DNA microarray in the study of neo-angiogenic components in tumor tissues was described and the ex vivo analysis in humans of circulating endothelial cells was proposed. The role of both genomic and pharmacogenomic profiles in the diagnosis and prediction of response to therapy and toxicity of both breast and colorectal cancer was described. A developmental model for the optimization of zoledronic acid (ZOL) antitumor activity based on either nanotechnological modification or molecular target fishing with DNA microarrays was discussed. The interdisciplinary network between pharmacologists, cellular and molecular biologists, biochemists and translational and clinical oncologists was encouraged and approved during the meeting in order to improve the efficacy of antitumor strategies.

Original languageEnglish
Pages (from-to)845-854
Number of pages10
JournalExpert Opinion on Biological Therapy
Volume8
Issue number6
DOIs
Publication statusPublished - Jun 2008

Fingerprint

Microarrays
Oligonucleotide Array Sequence Analysis
Drug delivery
Cell culture
Italy
Tumors
Cell Culture Techniques
zoledronic acid
Pharmaceutical Preparations
Proteomics
Neoplasms
DNA
Tissue Array Analysis
Tissue
Pharmacogenetics
Therapeutics
Microarray Analysis
Biochemistry
Electrophoresis
Molecular Biology

Keywords

  • Microarrays
  • Personalized medicine
  • Pharmacogenomics
  • Proteomics
  • ProtoArrays
  • Target therapy
  • Zoledronic acid

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology
  • Pharmacology

Cite this

@article{6d3a4337bb90419882c488e5563e2758,
title = "Highlights of the Annual Meeting of the Italian Association for Cell Cultures (AICC): New drug delivery strategies and technological platforms for diagnosis and therapy of tumors (Part I) 6-7 December 2007, Naples, Italy",
abstract = "The application of computational analysis to biochemistry and molecular biology techniques has allowed the design of advanced technological platforms such as DNA microarrays, proteomic analysis and tissue microarrays. These are useful in the diagnosis of tumors and in driving the choice of opportune therapeutic options. The use of target-based agents requires the determination of the molecular features of the tumors. During the AICC meeting four new advanced technological platforms were analyzed: DNA microarrays, ProtoArrays, tissue microarrays and proteomic analysis with differential in-gel electrophoresis (DIGE) and matrix-associated laser desorption ionization-time of flight (MALDI-TOF). The use of DNA microarray in the study of neo-angiogenic components in tumor tissues was described and the ex vivo analysis in humans of circulating endothelial cells was proposed. The role of both genomic and pharmacogenomic profiles in the diagnosis and prediction of response to therapy and toxicity of both breast and colorectal cancer was described. A developmental model for the optimization of zoledronic acid (ZOL) antitumor activity based on either nanotechnological modification or molecular target fishing with DNA microarrays was discussed. The interdisciplinary network between pharmacologists, cellular and molecular biologists, biochemists and translational and clinical oncologists was encouraged and approved during the meeting in order to improve the efficacy of antitumor strategies.",
keywords = "Microarrays, Personalized medicine, Pharmacogenomics, Proteomics, ProtoArrays, Target therapy, Zoledronic acid",
author = "Michele Caraglia and Monica Marra and Alfredo Budillon",
year = "2008",
month = "6",
doi = "10.1517/14712598.8.6.845",
language = "English",
volume = "8",
pages = "845--854",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - Highlights of the Annual Meeting of the Italian Association for Cell Cultures (AICC)

T2 - New drug delivery strategies and technological platforms for diagnosis and therapy of tumors (Part I) 6-7 December 2007, Naples, Italy

AU - Caraglia, Michele

AU - Marra, Monica

AU - Budillon, Alfredo

PY - 2008/6

Y1 - 2008/6

N2 - The application of computational analysis to biochemistry and molecular biology techniques has allowed the design of advanced technological platforms such as DNA microarrays, proteomic analysis and tissue microarrays. These are useful in the diagnosis of tumors and in driving the choice of opportune therapeutic options. The use of target-based agents requires the determination of the molecular features of the tumors. During the AICC meeting four new advanced technological platforms were analyzed: DNA microarrays, ProtoArrays, tissue microarrays and proteomic analysis with differential in-gel electrophoresis (DIGE) and matrix-associated laser desorption ionization-time of flight (MALDI-TOF). The use of DNA microarray in the study of neo-angiogenic components in tumor tissues was described and the ex vivo analysis in humans of circulating endothelial cells was proposed. The role of both genomic and pharmacogenomic profiles in the diagnosis and prediction of response to therapy and toxicity of both breast and colorectal cancer was described. A developmental model for the optimization of zoledronic acid (ZOL) antitumor activity based on either nanotechnological modification or molecular target fishing with DNA microarrays was discussed. The interdisciplinary network between pharmacologists, cellular and molecular biologists, biochemists and translational and clinical oncologists was encouraged and approved during the meeting in order to improve the efficacy of antitumor strategies.

AB - The application of computational analysis to biochemistry and molecular biology techniques has allowed the design of advanced technological platforms such as DNA microarrays, proteomic analysis and tissue microarrays. These are useful in the diagnosis of tumors and in driving the choice of opportune therapeutic options. The use of target-based agents requires the determination of the molecular features of the tumors. During the AICC meeting four new advanced technological platforms were analyzed: DNA microarrays, ProtoArrays, tissue microarrays and proteomic analysis with differential in-gel electrophoresis (DIGE) and matrix-associated laser desorption ionization-time of flight (MALDI-TOF). The use of DNA microarray in the study of neo-angiogenic components in tumor tissues was described and the ex vivo analysis in humans of circulating endothelial cells was proposed. The role of both genomic and pharmacogenomic profiles in the diagnosis and prediction of response to therapy and toxicity of both breast and colorectal cancer was described. A developmental model for the optimization of zoledronic acid (ZOL) antitumor activity based on either nanotechnological modification or molecular target fishing with DNA microarrays was discussed. The interdisciplinary network between pharmacologists, cellular and molecular biologists, biochemists and translational and clinical oncologists was encouraged and approved during the meeting in order to improve the efficacy of antitumor strategies.

KW - Microarrays

KW - Personalized medicine

KW - Pharmacogenomics

KW - Proteomics

KW - ProtoArrays

KW - Target therapy

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=45549084020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45549084020&partnerID=8YFLogxK

U2 - 10.1517/14712598.8.6.845

DO - 10.1517/14712598.8.6.845

M3 - Article

C2 - 18476796

AN - SCOPUS:45549084020

VL - 8

SP - 845

EP - 854

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 6

ER -